<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="and Sons Inc.Hoboken pmcid: 7049676 doi: 10.1002/hep4.1480HEP41480 : Review: Reviews" exact="Chronic" post="Viral Hepatitis: Current Management and Future Directions Do and"/>
 <result pre="Sons Inc.Hoboken pmcid: 7049676 doi: 10.1002/hep4.1480HEP41480 : Review: Reviews Chronic" exact="Viral" post="Hepatitis: Current Management and Future Directions Do and Reau"/>
 <result pre="has seen transformation in the strategies for identifying and managing" exact="viral hepatitis," post="most dramatically the transformation of hepatitis C virus from"/>
 <result pre="identifying and managing viral hepatitis, most dramatically the transformation of" exact="hepatitis" post="C virus from a mostly chronic affliction to a"/>
 <result pre="dramatically the transformation of hepatitis C virus from a mostly" exact="chronic" post="affliction to a curable disease that is accessible to"/>
 <result pre="C virus from a mostly chronic affliction to a curable" exact="disease" post="that is accessible to wide populations through direct‐acting antiviral"/>
 <result pre="wide populations through direct‐acting antiviral therapies. More recently, shifting of" exact="hepatitis" post="C virus burden to younger patients driven by intravenous"/>
 <result pre="will allow countries to work toward meeting goals of eliminating" exact="viral hepatitis" post="as a major public health threat. Concurrently, hepatitis B"/>
 <result pre="allow countries to work toward meeting goals of eliminating viral" exact="hepatitis" post="as a major public health threat. Concurrently, hepatitis B"/>
 <result pre="eliminating viral hepatitis as a major public health threat. Concurrently," exact="hepatitis" post="B virus has also seen advances in management using"/>
 <result pre="barriers. However, virologic cure remains elusive in the setting of" exact="viral" post="genetic persistence within the hepatocyte nucleus, even with suppressive"/>
 <result pre="biomarkers, and development of therapies targeting multiple pathways in the" exact="viral" post="pathogenic and replication pathway. Progress is additionally being made"/>
 <result pre="pathway. Progress is additionally being made on the management of" exact="hepatitis" post="D infection. This review summarizes the recent evolution in"/>
 <result pre="hepatitis D infection. This review summarizes the recent evolution in" exact="disease" post="characteristics, associated affected population, and changes in our understanding"/>
 <result pre="infections. We also discuss future directions in the management of" exact="viral hepatitis," post="including discussion on issues related to management before and"/>
 <result pre="We summarize recent advances in the identification and management of" exact="viral hepatitis," post="which hold the potential to markedly reduce disease burden"/>
 <result pre="of viral hepatitis, which hold the potential to markedly reduce" exact="disease" post="burden and therefore associated liver‐related complications. However further work"/>
 <result pre="advances have been made in the diagnosis and treatment of" exact="viral hepatitis." post="We summarize recent developments for viral hepatitis, including future"/>
 <result pre="and treatment of viral hepatitis. We summarize recent developments for" exact="viral hepatitis," post="including future directions for research and anticipated developments in"/>
 <result pre="for Gilead, Abbott, AbbVie. She researches for Abbott. Abbreviations AASLD" exact="American" post="Association for the Study of Liver Diseases cccDNA covalently"/>
 <result pre="for Abbott. Abbreviations AASLD American Association for the Study of" exact="Liver Diseases" post="cccDNA covalently closed circular DNA DAA direct‐acting antiviral EASL"/>
 <result pre="Abbott. Abbreviations AASLD American Association for the Study of Liver" exact="Diseases" post="cccDNA covalently closed circular DNA DAA direct‐acting antiviral EASL"/>
 <result pre="Association for the Study of the Liver ETV entecavir HBeAg" exact="hepatitis" post="B e antigen HBsAg hepatitis HBV surface antigen HBV"/>
 <result pre="the Liver ETV entecavir HBeAg hepatitis B e antigen HBsAg" exact="hepatitis" post="HBV surface antigen HBV hepatitis B virus HCV hepatitis"/>
 <result pre="hepatitis B e antigen HBsAg hepatitis HBV surface antigen HBV" exact="hepatitis" post="B virus HCV hepatitis C virus HDV hepatitis D"/>
 <result pre="HBsAg hepatitis HBV surface antigen HBV hepatitis B virus HCV" exact="hepatitis" post="C virus HDV hepatitis D virus HIV human immunodeficiency"/>
 <result pre="antigen HBV hepatitis B virus HCV hepatitis C virus HDV" exact="hepatitis" post="D virus HIV human immunodeficiency virus NA nucleos(t)ide analog"/>
 <result pre="HCV hepatitis C virus HDV hepatitis D virus HIV human" exact="immunodeficiency" post="virus NA nucleos(t)ide analog pgRNA pregenomic RNA PWID people"/>
 <result pre="sustained virologic response TAF tenofovir alafenamide TDF tenofovir disoproxil fumarate" exact="Viral hepatitis" post="continues to contribute to the burden of liver disease"/>
 <result pre="virologic response TAF tenofovir alafenamide TDF tenofovir disoproxil fumarate Viral" exact="hepatitis" post="continues to contribute to the burden of liver disease"/>
 <result pre="disoproxil fumarate Viral hepatitis continues to contribute to the burden" exact="of liver" post="disease in the United States, causing chronic hepatitis, cirrhosis"/>
 <result pre="fumarate Viral hepatitis continues to contribute to the burden of" exact="liver disease" post="in the United States, causing chronic hepatitis, cirrhosis and"/>
 <result pre="Viral hepatitis continues to contribute to the burden of liver" exact="disease" post="in the United States, causing chronic hepatitis, cirrhosis and"/>
 <result pre="the burden of liver disease in the United States, causing" exact="chronic hepatitis," post="cirrhosis and decompensated disease, liver cancer, and extrahepatic manifestations."/>
 <result pre="of liver disease in the United States, causing chronic hepatitis," exact="cirrhosis" post="and decompensated disease, liver cancer, and extrahepatic manifestations. However,"/>
 <result pre="the United States, causing chronic hepatitis, cirrhosis and decompensated disease," exact="liver cancer," post="and extrahepatic manifestations. However, this past decade has experienced"/>
 <result pre="notably with development of curative direct‐acting antiviral (DAA) therapies for" exact="chronic hepatitis" post="C virus (HCV) infection. Numerous advances in treatment development"/>
 <result pre="with development of curative direct‐acting antiviral (DAA) therapies for chronic" exact="hepatitis" post="C virus (HCV) infection. Numerous advances in treatment development"/>
 <result pre="advances in treatment development and strategies have been made in" exact="chronic hepatitis" post="B virus (HBV) and hepatitis D virus (HDV) as"/>
 <result pre="in treatment development and strategies have been made in chronic" exact="hepatitis" post="B virus (HBV) and hepatitis D virus (HDV) as"/>
 <result pre="have been made in chronic hepatitis B virus (HBV) and" exact="hepatitis" post="D virus (HDV) as well. This review aims to"/>
 <result pre="to summarize the current epidemiology and management strategies available for" exact="chronic" post="viral hepatitis, including future directions and areas where further"/>
 <result pre="summarize the current epidemiology and management strategies available for chronic" exact="viral hepatitis," post="including future directions and areas where further work is"/>
 <result pre="including future directions and areas where further work is needed." exact="Hepatitis" post="C: From Chronic Malady to Robust Cure Of the"/>
 <result pre="and areas where further work is needed. Hepatitis C: From" exact="Chronic" post="Malady to Robust Cure Of the viral hepatitides, none"/>
 <result pre="Hepatitis C: From Chronic Malady to Robust Cure Of the" exact="viral" post="hepatitides, none has seen as much transformation in available"/>
 <result pre="as much transformation in available pharmacologic treatment options as for" exact="chronic" post="HCV, which has been viewed previously as a chronic"/>
 <result pre="for chronic HCV, which has been viewed previously as a" exact="chronic" post="infection with only modest cure rates (sustained virologic response"/>
 <result pre="chronic HCV, which has been viewed previously as a chronic" exact="infection" post="with only modest cure rates (sustained virologic response [SVR]"/>
 <result pre="63%) with interferon‐based therapies.1 However, now it has become a" exact="disease" post="with multiple, well‐tolerated, finite therapies with SVR rates greater"/>
 <result pre="SVR rates greater than 95% across nearly all patient and" exact="viral" post="characteristics. Availability of such treatment has altered the landscape"/>
 <result pre="to these safe, effective treatments. Changing Epidemiology and Screening Recommendations" exact="Hepatitis" post="C remains one of the most prevalent chronic liver"/>
 <result pre="Screening Recommendations Hepatitis C remains one of the most prevalent" exact="chronic" post="liver diseases in the United States and beyond, but"/>
 <result pre="million.2 In a prevalence study of the Global Burden of" exact="Disease" post="project, HCV genotype 1 was most common (46.2% of"/>
 <result pre="cases), although other genotypes also contribute a large proportion of" exact="disease" post="burden (genotype 3: 30.1%; genotype 2, 4, and 6:"/>
 <result pre="million) in 2013 to 2016.5 In 2017, the Centers for" exact="Disease" post="Control estimated 44,700 new cases of acute HCV infection,"/>
 <result pre="the Centers for Disease Control estimated 44,700 new cases of" exact="acute" post="HCV infection, with an estimated 2.8 million people with"/>
 <result pre="acute HCV infection, with an estimated 2.8 million people with" exact="chronic" post="HCV in the United States.6 In the United States,"/>
 <result pre="in the United States.6 In the United States, although the" exact="disease" post="burden from HCV is decreasing, the clinical characteristics of"/>
 <result pre="from HCV is decreasing, the clinical characteristics of those with" exact="chronic" post="infection is evolving. Overall, HCV prevalence has decreasing nearly"/>
 <result pre="HCV is decreasing, the clinical characteristics of those with chronic" exact="infection" post="is evolving. Overall, HCV prevalence has decreasing nearly 2‐fold,"/>
 <result pre="who inject drugs (PWID), a population in whom prevalence of" exact="chronic" post="HCV has been estimated to be approximately 73.4% (range"/>
 <result pre="to be treatment‐naïve and without cirrhosis.10 However, despite anticipated decreased" exact="disease" post="incidence, disease burden is still expected to be substantial"/>
 <result pre="treatment‐naïve and without cirrhosis.10 However, despite anticipated decreased disease incidence," exact="disease" post="burden is still expected to be substantial based on"/>
 <result pre="modeling study finding that, driven primarily by a lack of" exact="disease" post="identification, 560,000 patients will not know about their chronic"/>
 <result pre="of disease identification, 560,000 patients will not know about their" exact="chronic" post="infection, 320,000 patients will die, 157,000 will develop hepatocellular"/>
 <result pre="their chronic infection, 320,000 patients will die, 157,000 will develop" exact="hepatocellular carcinoma," post="and 203,000 patients will develop decompensated cirrhosis in the"/>
 <result pre="will develop hepatocellular carcinoma, and 203,000 patients will develop decompensated" exact="cirrhosis" post="in the next 35 years.11 Optimizing HCV screening holds"/>
 <result pre="next 35 years.11 Optimizing HCV screening holds the key to" exact="disease" post="identification, yet effective screening has persistently been a challenge"/>
 <result pre="recently had called for both risk‐factor and cohort‐based approaches. The" exact="American" post="Association for the Study of Liver Diseases (AASLD) currently"/>
 <result pre="and cohort‐based approaches. The American Association for the Study of" exact="Liver Diseases" post="(AASLD) currently recommends one‐time screening for individuals with associated"/>
 <result pre="cohort‐based approaches. The American Association for the Study of Liver" exact="Diseases" post="(AASLD) currently recommends one‐time screening for individuals with associated"/>
 <result pre="targeted micro‐elimination may be an effective strategy to reduce HCV" exact="disease" post="burden on those at high risk for disease, and"/>
 <result pre="and medical societies. Evolution of Management Principles and Therapies for" exact="Chronic" post="Hepatitis C Virus Infection Our understanding of treatment‐eligible populations"/>
 <result pre="medical societies. Evolution of Management Principles and Therapies for Chronic" exact="Hepatitis" post="C Virus Infection Our understanding of treatment‐eligible populations has"/>
 <result pre="of Management Principles and Therapies for Chronic Hepatitis C Virus" exact="Infection" post="Our understanding of treatment‐eligible populations has developed in tandem"/>
 <result pre="treatments, current recommendations suggest treating all individuals diagnosed with HCV" exact="infection" post="regardless of risk for reinfection, hepatic fibrosis stage, or"/>
 <result pre="individuals diagnosed with HCV infection regardless of risk for reinfection," exact="hepatic fibrosis" post="stage, or prior‐treatment status. Additionally, the definition of SVR"/>
 <result pre="the definition of SVR has been shortened to be the" exact="absence of" post="viremia 12 weeks after treatment completion, as 99% of"/>
 <result pre="of patients with SVR12 have been found to have persistent" exact="viral" post="clearance at 24 weeks.19 This finding has reduced the"/>
 <result pre="used 24 or even 48 weeks to define HCV cure." exact="Multiple" post="societies have made recommendations for patient screening, including considerations"/>
 <result pre="us to move toward treating the largest proportion of the" exact="chronic" post="HCV‐infected population. Table 1 Society‐Based Recommendations for Screening and"/>
 <result pre="Table 1 Society‐Based Recommendations for Screening and Treatment for HCV" exact="Infection" post="Society Year of Guideline/Guidance Screening Indication for Treatment Comments"/>
 <result pre="generalized exposures that have since been removed (&quot;birth cohort&quot; testing)" exact="Generalized" post="population epidemic with high prevalence (whole population testing) All"/>
 <result pre="high prevalence (whole population testing) All individuals diagnosed with HCV" exact="infection" post="who are 12 years of age or older, regardless"/>
 <result pre="who are 12 years of age or older, regardless of" exact="disease" post="stage Strong recommendation, moderate quality of evidence 2018 (Treatment)"/>
 <result pre="and incarcerated individuals, with the exception of pregnant women AASLD," exact="Infectious" post="Disease Society of America (IDSA)13 2019 Risk behavior, risk"/>
 <result pre="incarcerated individuals, with the exception of pregnant women AASLD, Infectious" exact="Disease" post="Society of America (IDSA)13 2019 Risk behavior, risk exposure,"/>
 <result pre="Risk behavior, risk exposure, or other conditions* All patients with" exact="chronic" post="HCV, except for those with a short life expectancy"/>
 <result pre="All patients with chronic HCV, except for those with a" exact="short" post="life expectancy who cannot be remediated by HCV therapy,"/>
 <result pre="risk exposures or behaviors EASL80 2018 Screening strategies for HCV" exact="infection" post="should be defined according to the local epidemiology of"/>
 <result pre="should be treated Patients with decompensated (Child‐Pugh B or C)" exact="cirrhosis" post="and an indication for liver transplantation with a MELD"/>
 <result pre="birth cohort testing, and general population testing in areas of" exact="intermediate" post="to high seroprevalence (≥ 2%‐5%) Treatment is generally not"/>
 <result pre="(≥ 2%‐5%) Treatment is generally not recommended in patients with" exact="limited" post="life expectancy due to non‐live‐related comorbidities U.S. Preventive Services"/>
 <result pre="of transfusions or organ transplants, and ever incarcerated. Other conditions:" exact="HIV infection," post="sexually active about to start HIV postexposure prophylaxis, unexplained"/>
 <result pre="be used in patients with Child‐Pugh B or C decompensated" exact="cirrhosis" post="or in patients with previous episodes of decompensation. In"/>
 <result pre="Abbreviations: eGFR, estimated glomerular filtration rate; MELD, Model for End‐Stage" exact="Liver Disease;" post="MSM, men who have sex with men. (C) John"/>
 <result pre="of 65% to 75%, the landscape of antiviral therapy for" exact="chronic" post="HCV has expanded, with development of well‐tolerated, pan‐genotypic, all‐oral,"/>
 <result pre="the AASLD recommendations have developed a simplified approach to treat" exact="chronic" post="HCV, recommending glecaprevir/pibrentasvir for 8 weeks or sofosbuvir/velpatasvir for"/>
 <result pre="function and without comorbid infections.21 Table 2 Recommended Treatments for" exact="Chronic" post="HCV Infection* Regimen Treated Genotypes Duration (weeks) Efficacy Treatable"/>
 <result pre="Special Considerations Daclatasvir/sofosbuvir 1, 2, 3, 4 12 93%‐100% Decompensated" exact="cirrhosis" post="Add RBV for decompensated cirrhosis Following liver transplant with/without"/>
 <result pre="3, 4 12 93%‐100% Decompensated cirrhosis Add RBV for decompensated" exact="cirrhosis" post="Following liver transplant with/without cirrhosis HIV/HCV coinfection when antiretroviral"/>
 <result pre="cirrhosis Add RBV for decompensated cirrhosis Following liver transplant with/without" exact="cirrhosis" post="HIV/HCV coinfection when antiretroviral cannot be changed to accommodate"/>
 <result pre="(GT1,4) Elbasvir/grazoprevir 1, 3, 4 12 91%‐100% Treatment‐experienced (PEG/RBV) with/without" exact="cirrhosis" post="GT1a: Alternative regimen if high‐fold resistance variants to NS5A"/>
 <result pre="cirrhosis GT1a: Alternative regimen if high‐fold resistance variants to NS5A" exact="Severe" post="renal impairment GT3: Add sofosbuvir for PEG/RBV experienced with"/>
 <result pre="renal impairment GT3: Add sofosbuvir for PEG/RBV experienced with compensated" exact="cirrhosis" post="Not for decompensated cirrhosis or following liver transplant with"/>
 <result pre="sofosbuvir for PEG/RBV experienced with compensated cirrhosis Not for decompensated" exact="cirrhosis" post="or following liver transplant with cirrhosis Glecaprevir/pibrentasvir 1, 2,"/>
 <result pre="cirrhosis Not for decompensated cirrhosis or following liver transplant with" exact="cirrhosis" post="Glecaprevir/pibrentasvir 1, 2, 3, 4, 5, or 6 8"/>
 <result pre="6 8 94%‐100% Treatment‐experienced (PEG/RBV) with/without cirrhosis† Not for decompensated" exact="cirrhosis" post="or following liver transplant with cirrhosis Following liver transplant"/>
 <result pre="cirrhosis† Not for decompensated cirrhosis or following liver transplant with" exact="cirrhosis" post="Following liver transplant without cirrhosis 12‐week duration for special"/>
 <result pre="or following liver transplant with cirrhosis Following liver transplant without" exact="cirrhosis" post="12‐week duration for special populations Severe renal impairment 8‐week"/>
 <result pre="Following liver transplant without cirrhosis 12‐week duration for special populations" exact="Severe" post="renal impairment 8‐week duration for compensated cirrhosis Following kidney"/>
 <result pre="for special populations Severe renal impairment 8‐week duration for compensated" exact="cirrhosis" post="Following kidney transplant with/without cirrhosis Ledipasvir/sofosbuvir 1, 4, 5,"/>
 <result pre="impairment 8‐week duration for compensated cirrhosis Following kidney transplant with/without" exact="cirrhosis" post="Ledipasvir/sofosbuvir 1, 4, 5, or 6 12 93% to"/>
 <result pre="5, or 6 12 93% to 100% PEG/RBV experienced with/without" exact="cirrhosis" post="8‐week duration for treatment‐naïve, non‐black, HIV‐negative, HCV RNA &amp;lt;"/>
 <result pre="for treatment‐naïve, non‐black, HIV‐negative, HCV RNA &amp;lt; 106 IU/mL, without" exact="cirrhosis" post="Decompensated cirrhosis 24‐week duration and add RBV for decompensated"/>
 <result pre="non‐black, HIV‐negative, HCV RNA &amp;lt; 106 IU/mL, without cirrhosis Decompensated" exact="cirrhosis" post="24‐week duration and add RBV for decompensated cirrhosis with"/>
 <result pre="cirrhosis Decompensated cirrhosis 24‐week duration and add RBV for decompensated" exact="cirrhosis" post="with sofosbuvir failure Following liver transplant with/without cirrhosis (compensated"/>
 <result pre="for decompensated cirrhosis with sofosbuvir failure Following liver transplant with/without" exact="cirrhosis" post="(compensated or decompensated) Following kidney transplant with/without cirrhosis Add"/>
 <result pre="transplant with/without cirrhosis (compensated or decompensated) Following kidney transplant with/without" exact="cirrhosis" post="Add RBV for decompensated cirrhosis, following liver transplant Sofosbuvir/velpatasvir"/>
 <result pre="or 6 12 96%‐100% Treatment‐naïve, PEG/RBV, or DAA experienced without" exact="cirrhosis" post="(± decompensation) Add voxilaprevir for NS5A failure (including NS3"/>
 <result pre="Add voxilaprevir for NS5A failure (including NS3 protease inhibitors) with/without" exact="cirrhosis" post="(not for decompensated cirrhosis or following liver transplant with"/>
 <result pre="failure (including NS3 protease inhibitors) with/without cirrhosis (not for decompensated" exact="cirrhosis" post="or following liver transplant with cirrhosis) PEG/RBV with/without NS3"/>
 <result pre="protease inhibitor experienced 24‐week duration and add RBV for decompensated" exact="cirrhosis" post="with DAA failure including NS5A Following liver transplant with"/>
 <result pre="with DAA failure including NS5A Following liver transplant with decompensated" exact="cirrhosis" post="*Simplified regimen for treatment‐naïve, nonpregnant patient with normal renal"/>
 <result pre="nonpregnant patient with normal renal function and HCV mono‐infection, without" exact="cirrhosis" post="or history of liver transplantation: glecaprevir/pibrentasvir for 8 weeks"/>
 <result pre="normal renal function and HCV mono‐infection, without cirrhosis or history" exact="of liver" post="transplantation: glecaprevir/pibrentasvir for 8 weeks or sofosbuvir/velpatasvir for 12"/>
 <result pre="for 12 weeks. †Also non‐NS5A failure with/without cirrhosis. Abbreviations: CKD," exact="chronic" post="kidney disease; PEG, pegylated interferon; RBV, ribavirin. (C) John"/>
 <result pre="12 weeks. †Also non‐NS5A failure with/without cirrhosis. Abbreviations: CKD, chronic" exact="kidney disease;" post="PEG, pegylated interferon; RBV, ribavirin. (C) John Wiley &amp;amp;"/>
 <result pre="safety and efficacy across different treatment groups, current therapies for" exact="chronic" post="HCV infection are safe and effective across a variety"/>
 <result pre="efficacy across different treatment groups, current therapies for chronic HCV" exact="infection" post="are safe and effective across a variety of patient"/>
 <result pre="variety of patient populations, with high SVR rates in decompensated" exact="cirrhosis" post="(&amp;gt;85%), end‐stage renal disease (&amp;gt;95%), human immunodeficiency virus co‐infection"/>
 <result pre="populations, with high SVR rates in decompensated cirrhosis (&amp;gt;85%), end‐stage" exact="renal disease" post="(&amp;gt;95%), human immunodeficiency virus co‐infection (&amp;gt;95%), or history of"/>
 <result pre="with high SVR rates in decompensated cirrhosis (&amp;gt;85%), end‐stage renal" exact="disease" post="(&amp;gt;95%), human immunodeficiency virus co‐infection (&amp;gt;95%), or history of"/>
 <result pre="rates in decompensated cirrhosis (&amp;gt;85%), end‐stage renal disease (&amp;gt;95%), human" exact="immunodeficiency" post="virus co‐infection (&amp;gt;95%), or history of prior DAA failure"/>
 <result pre="24, 25 High SVR despite multiple patient comorbidities targeting all" exact="viral" post="genotypes thus raises the question about whether defining &quot;special"/>
 <result pre="Organization has set five service coverage targets for elimination of" exact="viral hepatitis" post="as a public health threat by 2030, including targeting"/>
 <result pre="has set five service coverage targets for elimination of viral" exact="hepatitis" post="as a public health threat by 2030, including targeting"/>
 <result pre="would ultimately only treat the 7% to 11% with known" exact="chronic" post="HCV infection, but it does not account for those"/>
 <result pre="from 2013 to 2016, that 89.4% of patients diagnosed with" exact="chronic" post="HCV infection did not receive prescription for antiviral therapy."/>
 <result pre="to 2016, that 89.4% of patients diagnosed with chronic HCV" exact="infection" post="did not receive prescription for antiviral therapy. In this"/>
 <result pre="treatment could be offered: HCV screening, diagnosis, patient communication regarding" exact="chronic" post="infection, care linkage, and fibrosis staging. Concurrently, development of"/>
 <result pre="subsequent provision implementation strategies will be important to reduce population" exact="disease" post="burden. Specialty care access is another area for future"/>
 <result pre="in treating infected patients when led by nurses,32 pharmacists,33 and" exact="primary" post="care providers.34 As more chronically infected patients are identified,"/>
 <result pre="various genotypes (n = 44 with 36 lung and 8" exact="heart" post="transplants) who received 4 weeks of sofosbuvir and velpatasvir"/>
 <result pre="patients (100%) were alive with excellent graft function and undetectable" exact="viral" post="load 6 months after transplantation.37 Further data are needed"/>
 <result pre="timing. DAA‐treatable populations have expanded to include those with end‐stage" exact="renal disease," post="coinfection with HBV or human immunodeficiency virus, and pediatric"/>
 <result pre="those with end‐stage renal disease, coinfection with HBV or human" exact="immunodeficiency" post="virus, and pediatric populations. However, some populations are still"/>
 <result pre="to receive treatment. Additionally, guidance for treatment for those with" exact="acute" post="HCV infection (occurring in the first 6 months of"/>
 <result pre="treatment. Additionally, guidance for treatment for those with acute HCV" exact="infection" post="(occurring in the first 6 months of infection) has"/>
 <result pre="after diagnosis and without a waiting period to assess for" exact="viral" post="clearance.13 If DAA treatments become more cost‐effective in the"/>
 <result pre="optimal treatment regimen and timing may become useful in preventing" exact="acute" post="HCV infection from progressing to chronic infection, and minimizing"/>
 <result pre="regimen and timing may become useful in preventing acute HCV" exact="infection" post="from progressing to chronic infection, and minimizing comorbidity resulting"/>
 <result pre="become useful in preventing acute HCV infection from progressing to" exact="chronic" post="infection, and minimizing comorbidity resulting from acute infection and"/>
 <result pre="from progressing to chronic infection, and minimizing comorbidity resulting from" exact="acute" post="infection and transmission with horizontal spread. Despite robust SVR"/>
 <result pre="progressing to chronic infection, and minimizing comorbidity resulting from acute" exact="infection" post="and transmission with horizontal spread. Despite robust SVR rates"/>
 <result pre="and minimizing comorbidity resulting from acute infection and transmission with" exact="horizontal" post="spread. Despite robust SVR rates in most patients, the"/>
 <result pre="presence of HCV resistance–associated amino acid substitutions can result in" exact="lower" post="cure rates in some patient groups, including genotype 1a/3,"/>
 <result pre="prior interferon‐based treatments. Developing strategies to detect and account for" exact="viral" post="resistance to DAAs will be necessary, as with continued"/>
 <result pre="management, particularly regarding who need closer monitoring. Although patients with" exact="cirrhosis" post="will still require indefinite subspecialty care, determination of surveillance"/>
 <result pre="there is a question regarding the need for surveillance for" exact="hepatocellular carcinoma" post="in these patients, and one study reported the cost‐effectiveness"/>
 <result pre="is a question regarding the need for surveillance for hepatocellular" exact="carcinoma" post="in these patients, and one study reported the cost‐effectiveness"/>
 <result pre="research is those with obesity, owing to the risk for" exact="nonalcoholic fatty liver disease," post="which has arisen as the most prevalent chronic liver"/>
 <result pre="is those with obesity, owing to the risk for nonalcoholic" exact="fatty liver disease," post="which has arisen as the most prevalent chronic liver"/>
 <result pre="those with obesity, owing to the risk for nonalcoholic fatty" exact="liver disease," post="which has arisen as the most prevalent chronic liver"/>
 <result pre="fatty liver disease, which has arisen as the most prevalent" exact="chronic" post="liver disease in the world and the fastest‐growing indication"/>
 <result pre="liver disease, which has arisen as the most prevalent chronic" exact="liver disease" post="in the world and the fastest‐growing indication for liver"/>
 <result pre="disease, which has arisen as the most prevalent chronic liver" exact="disease" post="in the world and the fastest‐growing indication for liver"/>
 <result pre="41 A recent nationwide study found a 160% increase in" exact="NAFLD" post="prevalence in the past 30 years, despite stable or"/>
 <result pre="increase in NAFLD prevalence in the past 30 years, despite" exact="stable" post="or decreasing prevalence of chronic HBV, HCV, and alcoholic"/>
 <result pre="the past 30 years, despite stable or decreasing prevalence of" exact="chronic" post="HBV, HCV, and alcoholic liver disease.7 Weight gain after"/>
 <result pre="despite stable or decreasing prevalence of chronic HBV, HCV, and" exact="alcoholic" post="liver disease.7 Weight gain after HCV cure has been"/>
 <result pre="but is clinically important given the high worldwide prevalence of" exact="obesity" post="and the multisystemic complications associated with excess weight, including"/>
 <result pre="including NAFLD44 (Table 3). Table 3 Indications for Treatment of" exact="Chronic" post="HBV Infection Indications to Initiate Treatment AASLD Treat Potentially"/>
 <result pre="(Table 3). Table 3 Indications for Treatment of Chronic HBV" exact="Infection" post="Indications to Initiate Treatment AASLD Treat Potentially Treat* Do"/>
 <result pre="Can be treated Do not treat HBeAg‐positive or HBeAg‐negative HBeAg‐positive" exact="chronic" post="HBV infection and age &amp;gt;30 years, regardless of severity"/>
 <result pre="treated Do not treat HBeAg‐positive or HBeAg‐negative HBeAg‐positive chronic HBV" exact="infection" post="and age &amp;gt;30 years, regardless of severity of liver"/>
 <result pre="chronic HBV infection and age &amp;gt;30 years, regardless of severity" exact="of liver" post="histological lesions HBeAg‐positive or negative Undetectable HBV DNA, normal"/>
 <result pre="normal ALT, and mild or no liver necroinflammation and fibrosis" exact="Chronic" post="HBV infection† Cirrhosis with/without decompensated and any detectable HBV"/>
 <result pre="with/without decompensated and any detectable HBV DNA, regardless of ALT" exact="Chronic" post="HBV infection and family history of HCC or cirrhosis"/>
 <result pre="and any detectable HBV DNA, regardless of ALT Chronic HBV" exact="infection" post="and family history of HCC or cirrhosis and extrahepatic"/>
 <result pre="ALT Chronic HBV infection and family history of HCC or" exact="cirrhosis" post="and extrahepatic manifestations HBV DNA &amp;gt; 20,000 IU/mL and"/>
 <result pre="&amp;gt; 2× ULN, regardless of degree of fibrosis Note ALT" exact="upper" post="limit of normal is defined as 35 U/L for"/>
 <result pre="moderate liver necroinflammation or fibrosis. Abbreviations: ALT, alanine aminotransferase; CHB," exact="chronic hepatitis" post="B; ULN, upper limit of normal. (C) John Wiley"/>
 <result pre="liver necroinflammation or fibrosis. Abbreviations: ALT, alanine aminotransferase; CHB, chronic" exact="hepatitis" post="B; ULN, upper limit of normal. (C) John Wiley"/>
 <result pre="fibrosis. Abbreviations: ALT, alanine aminotransferase; CHB, chronic hepatitis B; ULN," exact="upper" post="limit of normal. (C) John Wiley &amp;amp; Sons, Ltd,"/>
 <result pre="upper limit of normal. (C) John Wiley &amp;amp; Sons, Ltd," exact="Hepatitis" post="B Virus: Still in Need of Definitive Cure Although"/>
 <result pre="Still in Need of Definitive Cure Although current therapies for" exact="chronic" post="HBV are associated with high viral suppression rates, patients"/>
 <result pre="Although current therapies for chronic HBV are associated with high" exact="viral" post="suppression rates, patients generally require lifelong therapy, and true"/>
 <result pre="clearance remains elusive. HBV management has generally been approached with" exact="viral" post="suppression using antiviral therapies. This section will detail recent"/>
 <result pre="effective first‐line antiviral and future therapeutic strategies under investigation. Evolving" exact="Disease" post="Burden and Epidemiology HBV remains a global public health"/>
 <result pre="States, HBsAg seroprevalence was 0.27%, corresponding to 843,724 individuals with" exact="chronic" post="HBV infection.45 Advances in Vaccination Improvements in HBV vaccination"/>
 <result pre="Improvements in HBV vaccination strategy is one key to reducing" exact="disease" post="burden. Universal vaccination programs in hyperendemic regions, such as"/>
 <result pre="in Taiwan, have been associated with reduced HBV carrier and" exact="liver cancer" post="rates.46, 47 Additionally, ease of vaccination dosing would increase"/>
 <result pre="Taiwan, have been associated with reduced HBV carrier and liver" exact="cancer" post="rates.46, 47 Additionally, ease of vaccination dosing would increase"/>
 <result pre="aged 18 years or older for vaccination against HBV.49 Management:" exact="Viral" post="Suppression Is Key If treatment is indicated, the choice"/>
 <result pre="agent should be a medication with a high barrier to" exact="viral" post="resistance. Studies of pivotal trials have revealed low long‐term"/>
 <result pre="more efficient hepatocyte drug delivery compared with TDF, which allows" exact="lower" post="allowable TAF doses. For this reason, TAF may be"/>
 <result pre="TAF doses. For this reason, TAF may be associated with" exact="lower" post="risk for renal dysfunction and reduced bone mineral density"/>
 <result pre="of two large, randomized, phase 3 controlled trials found significantly" exact="lower" post="bone mineral density at 96 weeks in patients receiving"/>
 <result pre="−1.2% TAF; P &amp;lt; 0.001), with TAF noninferiority for HBV" exact="viral" post="suppression.54 The recent 2017 EASL Guidelines and 2018 AASLD"/>
 <result pre="TAF over TDF, including advanced age, reduced bone density, and" exact="chronic" post="renal insufficiency (Table 4).51, 52 Table 4 Considerations for"/>
 <result pre="over TDF, including advanced age, reduced bone density, and chronic" exact="renal insufficiency" post="(Table 4).51, 52 Table 4 Considerations for Antiviral Selection"/>
 <result pre="risks of renal and bone complications TAF is associated with" exact="lower" post="rates of bone and renal abnormalities than TDF In"/>
 <result pre="than TDF In cases of suspected TDF‐associated renal dysfunction and/or" exact="bone disease," post="TDF should be discontinued and substituted with TAF or"/>
 <result pre="ETV or TAF over TDF Age &amp;gt; 60 years Bone" exact="disease" post="Chronic use of medications that worsen bone density (including"/>
 <result pre="or TAF over TDF Age &amp;gt; 60 years Bone disease" exact="Chronic" post="use of medications that worsen bone density (including steroids)"/>
 <result pre="that worsen bone density (including steroids) History of fragility fractures" exact="Osteoporosis" post="Renal dysfunction eGFR &amp;lt;60 mL/min/1.73 m2 Albuminuria &amp;gt;30 mg/24"/>
 <result pre="worsen bone density (including steroids) History of fragility fractures Osteoporosis" exact="Renal" post="dysfunction eGFR &amp;lt;60 mL/min/1.73 m2 Albuminuria &amp;gt;30 mg/24 hours"/>
 <result pre="Albuminuria &amp;gt;30 mg/24 hours or urinalysis with moderate qualitative proteinuria" exact="Hypophosphatemia" post="(&amp;lt;2.5 mg/dL) On hemodialysis Recommendation statements Patients on TDF"/>
 <result pre="TDF at risk of development and/or with underlying renal or" exact="bone disease" post="should be considered for a switch to ETV or"/>
 <result pre="at risk of development and/or with underlying renal or bone" exact="disease" post="should be considered for a switch to ETV or"/>
 <result pre="treatment goals when developing drugs targeting multiple pathways in the" exact="viral" post="replication pathway. Although the ideal goal would be to"/>
 <result pre="cure&quot;), this may be unrealistic due to the persistence of" exact="viral" post="covalently closed circular DNA (cccDNA) in the liver, and"/>
 <result pre="undetectable HBV DNA 6 months after treatment, is considered an" exact="intermediate" post="goal for antiviral therapies.55, 56 Designation of these clear‐but‐distinct"/>
 <result pre="discontinuation. Decrease in quantitative HBsAg levels has been associated with" exact="viral" post="clearance,57, 58 and is routinely monitored over the course"/>
 <result pre="treatment, allowing differentiation of immune tolerance and immune clearance in" exact="hepatitis" post="B e antigen (HBeAg)‐positive patients.59 Hepatitis B core‐related antigen"/>
 <result pre="and immune clearance in hepatitis B e antigen (HBeAg)‐positive patients.59" exact="Hepatitis" post="B core‐related antigen (HBcrAg) is one new biomarker under"/>
 <result pre="been correlated with cccDNA levels, can predict posttreatment recurrence of" exact="hepatocellular carcinoma" post="during antiviral therapy, and can identify patients who may"/>
 <result pre="correlated with cccDNA levels, can predict posttreatment recurrence of hepatocellular" exact="carcinoma" post="during antiviral therapy, and can identify patients who may"/>
 <result pre="may successfully discontinue therapy.60, 61, 62 Pregenomic RNA (pgRNA), an" exact="intermediate" post="genome‐length RNA transcribed from cccDNA, has also been associated"/>
 <result pre="with cccDNA levels and may be a clinical marker for" exact="viral" post="replication activity.59 These viral molecules hold promise as surrogate"/>
 <result pre="may be a clinical marker for viral replication activity.59 These" exact="viral" post="molecules hold promise as surrogate markers for HBV viral"/>
 <result pre="These viral molecules hold promise as surrogate markers for HBV" exact="viral" post="activity in conjunction with standard biomarkers in present clinical"/>
 <result pre="standard biomarkers in present clinical use. Current approved treatments for" exact="chronic" post="HBV fall into two classes: nucleos(t)ide reverse transcriptase inhibitors,"/>
 <result pre="prodrugs besifovir and metacavir.63 Unfortunately, even though NAs effectively suppress" exact="viral" post="replication, they do not lead to virologic cure. Thus,"/>
 <result pre="cure. Thus, most patients require indefinite oral therapy, as although" exact="partial" post="functional cure is readily achievable with current therapies, complete"/>
 <result pre="although partial functional cure is readily achievable with current therapies," exact="complete" post="functional cure is achieved in a minority and virologic"/>
 <result pre="cure in even fewer patients.64 Development of new treatments for" exact="chronic" post="HBV is needed, concurrently with a better understanding of"/>
 <result pre="treatments to theoretically achieve virologic cure, inhibition of cccDNA and" exact="viral" post="replication is needed. Towards this goal, multiple drugs targeting"/>
 <result pre="drugs targeting multiple therapeutic targets (Table 5) are in development." exact="Viral" post="entry inhibitors such as Myrcludex B competes for viral"/>
 <result pre="development. Viral entry inhibitors such as Myrcludex B competes for" exact="viral" post="binding for viral entry into the hepatocyte and would"/>
 <result pre="inhibitors such as Myrcludex B competes for viral binding for" exact="viral" post="entry into the hepatocyte and would play a role"/>
 <result pre="role in treating both HBV and HDV.63 Other targets include" exact="viral" post="migration to the hepatocyte nucleus, viral uncoating, cccDNA production"/>
 <result pre="HDV.63 Other targets include viral migration to the hepatocyte nucleus," exact="viral" post="uncoating, cccDNA production and integration, viral replication through DNA"/>
 <result pre="to the hepatocyte nucleus, viral uncoating, cccDNA production and integration," exact="viral" post="replication through DNA synthesis, as well as the production"/>
 <result pre="DNA synthesis, as well as the production and secretion of" exact="viral" post="particles (Dane particles).55 New drug development coupled with research"/>
 <result pre="coupled with research on combination therapies hold promise for effective" exact="viral" post="virologic cure. Table 5 Therapeutic Targets for HBV Drugs"/>
 <result pre="migration to nuclear periphery and nuclear import Tubulin production inhibitor" exact="Viral" post="uncoating and intranuclear rcDNA release No current drugs cccDNA"/>
 <result pre="progeny rcDNA and capsid packaging Capsid assembly modulators Interferon alpha" exact="Viral" post="replication through DNA synthesis Nucleoside analogs Capsid incorporation of"/>
 <result pre="alpha Abbreviations: ccc, covalently closed circular; DNA, deoxyribonucleic acid; HBsAg," exact="hepatitis" post="B virus surface antigen; pg, pregenomic; rc, relaxed circular;"/>
 <result pre="that requires HBsAg expression as an envelope protein to mediate" exact="viral" post="entry and complete its life cycle. HDV infection presents"/>
 <result pre="expression as an envelope protein to mediate viral entry and" exact="complete" post="its life cycle. HDV infection presents as either HBV‐HDV"/>
 <result pre="to mediate viral entry and complete its life cycle. HDV" exact="infection" post="presents as either HBV‐HDV coinfection or HDV superinfection in"/>
 <result pre="as either HBV‐HDV coinfection or HDV superinfection in those with" exact="chronic" post="HBV infection. HBV‐HDV coinfection is considered among the most"/>
 <result pre="HBV‐HDV coinfection is considered among the most severe forms of" exact="viral hepatitis," post="with risk of developing acute liver failure as well"/>
 <result pre="most severe forms of viral hepatitis, with risk of developing" exact="acute" post="liver failure as well as higher risk for development"/>
 <result pre="severe forms of viral hepatitis, with risk of developing acute" exact="liver failure" post="as well as higher risk for development of cirrhosis,"/>
 <result pre="failure as well as higher risk for development of cirrhosis," exact="hepatocellular carcinoma," post="and mortality compared with HBV infection alone.65, 66 A"/>
 <result pre="development of cirrhosis, hepatocellular carcinoma, and mortality compared with HBV" exact="infection" post="alone.65, 66 A recent systematic review and meta‐analysis of"/>
 <result pre="NHANES revealed HDV antibody seropositivity in 33% to 47% of" exact="adult" post="HBsAg carriers.68 This suggests higher HDV disease burden than"/>
 <result pre="to 47% of adult HBsAg carriers.68 This suggests higher HDV" exact="disease" post="burden than previous believed (previously estimated to be only"/>
 <result pre="5%).69 Further epidemiologic studies are needed to clarify the current" exact="disease" post="burden of HDV, which in turn may help identify"/>
 <result pre="strategies. Current recommendations for HDV screening suggest testing for human" exact="immunodeficiency" post="virus (HIV)‐positive patients, persons who inject drugs, men who"/>
 <result pre="highly endemic regions.52 The only currently recommended treatment for HDV" exact="infection" post="is pegylated interferon‐alfa 2a or 2b, which is associated"/>
 <result pre="contribute further efficacy,71 but may nevertheless be indicated if concomitant" exact="chronic" post="HBV DNA were present. Newer agents are under investigation,"/>
 <result pre="HDV prenylation inhibitors (Lonafarnib), virion secretion inhibitors (REP 2139), and" exact="viral" post="entry inhibitors (Myrcludex B) in phase 3 studies.72, 73,"/>
 <result pre="Conclusion Rapid, significant advances in the diagnosis and management for" exact="viral hepatitis" post="has changed the landscape of the treatment of viral"/>
 <result pre="Rapid, significant advances in the diagnosis and management for viral" exact="hepatitis" post="has changed the landscape of the treatment of viral"/>
 <result pre="viral hepatitis has changed the landscape of the treatment of" exact="viral hepatitis" post="in the past decade. Treatment options for hepatitis C"/>
 <result pre="hepatitis has changed the landscape of the treatment of viral" exact="hepatitis" post="in the past decade. Treatment options for hepatitis C"/>
 <result pre="of viral hepatitis in the past decade. Treatment options for" exact="hepatitis" post="C currently hold the potential for eradication in the"/>
 <result pre="if reduction in new cases can be coupled with widespread" exact="disease" post="identification and treatment. Clearly defining hepatitis B cure endpoints,"/>
 <result pre="be coupled with widespread disease identification and treatment. Clearly defining" exact="hepatitis" post="B cure endpoints, in conjunction with effective biomarkers and"/>
 <result pre="and therapies targeting multiple pathways that focus on prevention of" exact="viral" post="replication machinery, holds the key to virologic cure and"/>
 <result pre="the key to virologic cure and ultimately eradication. Progress on" exact="hepatitis" post="D infection grows in tandem with that of hepatitis"/>
 <result pre="to virologic cure and ultimately eradication. Progress on hepatitis D" exact="infection" post="grows in tandem with that of hepatitis B, and"/>
 <result pre="on hepatitis D infection grows in tandem with that of" exact="hepatitis" post="B, and future work in epidemiology and pharmacotherapy are"/>
 <result pre="future work in epidemiology and pharmacotherapy are needed. Finally, although" exact="hepatitis" post="A and hepatitis E are generally approached usin supportive"/>
 <result pre="epidemiology and pharmacotherapy are needed. Finally, although hepatitis A and" exact="hepatitis" post="E are generally approached usin supportive measures due their"/>
 <result pre="is needed for the minority of patients who develop protracted" exact="or chronic" post="disease. Finally, in all viral hepatitides, the recognition of"/>
 <result pre="needed for the minority of patients who develop protracted or" exact="chronic" post="disease. Finally, in all viral hepatitides, the recognition of"/>
 <result pre="patients who develop protracted or chronic disease. Finally, in all" exact="viral" post="hepatitides, the recognition of high‐risk groups coupled with development"/>
 <result pre="editing of this manuscript. References References 1MannsM, WedemeyerH, CornbergM. Treating" exact="viral hepatitis" post="C: efficacy, side effects, and complications. Gut2006;55:1350‐1359.16905701 2collab: World"/>
 <result pre="of this manuscript. References References 1MannsM, WedemeyerH, CornbergM. Treating viral" exact="hepatitis" post="C: efficacy, side effects, and complications. Gut2006;55:1350‐1359.16905701 2collab: World"/>
 <result pre="Annex B. WHO estimates of the prevalence and incidence of" exact="hepatitis" post="C virus infection by WHO region, 2015. Global hepatitis"/>
 <result pre="WHO estimates of the prevalence and incidence of hepatitis C" exact="virus infection" post="by WHO region, 2015. Global hepatitis report 2017. 3MessinaJP,"/>
 <result pre="estimates of the prevalence and incidence of hepatitis C virus" exact="infection" post="by WHO region, 2015. Global hepatitis report 2017. 3MessinaJP,"/>
 <result pre="of hepatitis C virus infection by WHO region, 2015. Global" exact="hepatitis" post="report 2017. 3MessinaJP, HumphreysI, FlaxmanA, BrownA, CookeGS, PybusOG, et"/>
 <result pre="BrownA, CookeGS, PybusOG, et al. Global distribution and prevalence of" exact="hepatitis" post="C virus genotypes. Hepatology2015;61:77‐87.25069599 4PetruzzielloA, MariglianoS, LoquercioG, CozzolinoA, CacciapuotiC."/>
 <result pre="genotypes. Hepatology2015;61:77‐87.25069599 4PetruzzielloA, MariglianoS, LoquercioG, CozzolinoA, CacciapuotiC. Global epidemiology of" exact="hepatitis" post="C virus infection: an up‐date of the distribution and"/>
 <result pre="virus infection: an up‐date of the distribution and circulation of" exact="hepatitis" post="C virus genotypes. World J Gastroenterol2016;22:7824.27678366 5HofmeisterMG, RosenthalEM, BarkerLK,"/>
 <result pre="RosenthalEM, BarkerLK, RosenbergES, BarrancoMA, HallEW, et al. Estimating prevalence of" exact="hepatitis" post="C virus infection in the United States, 2013‐2016. Hepatology2019;69:1020‐1031.30398671"/>
 <result pre="RosenbergES, BarrancoMA, HallEW, et al. Estimating prevalence of hepatitis C" exact="virus infection" post="in the United States, 2013‐2016. Hepatology2019;69:1020‐1031.30398671 6collab: Centers for"/>
 <result pre="BarrancoMA, HallEW, et al. Estimating prevalence of hepatitis C virus" exact="infection" post="in the United States, 2013‐2016. Hepatology2019;69:1020‐1031.30398671 6collab: Centers for"/>
 <result pre="infection in the United States, 2013‐2016. Hepatology2019;69:1020‐1031.30398671 6collab: Centers for" exact="Disease" post="Control and Prevention . Surveillance for viral hepatitis—United States,"/>
 <result pre="6collab: Centers for Disease Control and Prevention . Surveillance for" exact="viral" post="hepatitis—United States, 2017. Division of Viral Hepatitis. http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/Commentary.htm; 2018."/>
 <result pre="Prevention . Surveillance for viral hepatitis—United States, 2017. Division of" exact="Viral" post="Hepatitis. http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/Commentary.htm; 2018. 7YounossiZM, StepanovaM, YounossiY, GolabiP, MishraA, RafiqN,"/>
 <result pre="7YounossiZM, StepanovaM, YounossiY, GolabiP, MishraA, RafiqN, et al. Epidemiology of" exact="chronic" post="liver diseases in the USA in the past three"/>
 <result pre="Jul 31. 10.1136/gutjnl-2019-318813. [Epub ahead of print] 8collab: Centers for" exact="Disease" post="Control and Prevention (CDC) CfDCaP . Surveillance for viral"/>
 <result pre="for Disease Control and Prevention (CDC) CfDCaP . Surveillance for" exact="viral" post="hepatitis—United States, 2016; 2016. 9NelsonPK, MathersBM, CowieB, HaganH, Des"/>
 <result pre="CowieB, HaganH, Des JarlaisD, HoryniakD, et al. Global epidemiology of" exact="hepatitis" post="B and hepatitis C in people who inject drugs:"/>
 <result pre="JarlaisD, HoryniakD, et al. Global epidemiology of hepatitis B and" exact="hepatitis" post="C in people who inject drugs: results of systematic"/>
 <result pre="of systematic reviews. Lancet2011;378:571‐583.21802134 10collab: Decision Resources Group . Report:" exact="Hepatitis" post="C Virus: Disease Landscape and Forecast; Jan 2017. 11ChhatwalJ,"/>
 <result pre="Lancet2011;378:571‐583.21802134 10collab: Decision Resources Group . Report: Hepatitis C Virus:" exact="Disease" post="Landscape and Forecast; Jan 2017. 11ChhatwalJ, WangX, AyerT, KabiriM,"/>
 <result pre="Jan 2017. 11ChhatwalJ, WangX, AyerT, KabiriM, ChungRT, HurC, et al." exact="Hepatitis" post="C disease burden in the United States in the"/>
 <result pre="11ChhatwalJ, WangX, AyerT, KabiriM, ChungRT, HurC, et al. Hepatitis C" exact="disease" post="burden in the United States in the era of"/>
 <result pre="HatiaRI, DrobeniucJ, WardJW, TeoCG. Cost‐effectiveness of strategies for testing current" exact="hepatitis" post="C virus infection. Hepatology2015;62:1396‐1404.26126725 13collab: AASLD‐IDSA HCV Guidance Panel"/>
 <result pre="WardJW, TeoCG. Cost‐effectiveness of strategies for testing current hepatitis C" exact="virus infection." post="Hepatology2015;62:1396‐1404.26126725 13collab: AASLD‐IDSA HCV Guidance Panel . Hepatitis C"/>
 <result pre="C virus infection. Hepatology2015;62:1396‐1404.26126725 13collab: AASLD‐IDSA HCV Guidance Panel ." exact="Hepatitis" post="C guidance 2018 update: AASLD‐IDSA recommendations for testing, managing,"/>
 <result pre="guidance 2018 update: AASLD‐IDSA recommendations for testing, managing, and treating" exact="hepatitis" post="C virus infection. Clin Infect Dis2018;67:1477‐1492.30215672 14collab: U.S. Preventive"/>
 <result pre="update: AASLD‐IDSA recommendations for testing, managing, and treating hepatitis C" exact="virus infection." post="Clin Infect Dis2018;67:1477‐1492.30215672 14collab: U.S. Preventive Services Task Force"/>
 <result pre="14collab: U.S. Preventive Services Task Force . Draft update summary:" exact="hepatitis" post="C virus infection in adolescents and adults: screening. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryDraft/hepatitis-c-screening1."/>
 <result pre="Preventive Services Task Force . Draft update summary: hepatitis C" exact="virus infection" post="in adolescents and adults: screening. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryDraft/hepatitis-c-screening1. Accessed August 29,"/>
 <result pre="Services Task Force . Draft update summary: hepatitis C virus" exact="infection" post="in adolescents and adults: screening. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryDraft/hepatitis-c-screening1. Accessed August 29,"/>
 <result pre="2019. 15EckmanMH, WardJW, ShermanKE. Cost effectiveness of universal screening for" exact="hepatitis" post="C virus infection in the era of direct‐acting, pangenotypic"/>
 <result pre="WardJW, ShermanKE. Cost effectiveness of universal screening for hepatitis C" exact="virus infection" post="in the era of direct‐acting, pangenotypic treatment regimens. Clin"/>
 <result pre="ShermanKE. Cost effectiveness of universal screening for hepatitis C virus" exact="infection" post="in the era of direct‐acting, pangenotypic treatment regimens. Clin"/>
 <result pre="16HeT, LiK, RobertsMS, SpauldingAC, AyerT, GrefenstetteJJ, et al. Prevention of" exact="hepatitis" post="C by screening and treatment in US prisons. Ann"/>
 <result pre="Intern Med2016;164:84‐92.26595252 17HahnéSJ, VeldhuijzenIK, WiessingL, LimT‐A, SalminenM, van de LaarM." exact="Infection" post="with hepatitis B and C virus in Europe: a"/>
 <result pre="17HahnéSJ, VeldhuijzenIK, WiessingL, LimT‐A, SalminenM, van de LaarM. Infection with" exact="hepatitis" post="B and C virus in Europe: a systematic review"/>
 <result pre="weeks to determine the sustained virologic response in patients with" exact="hepatitis" post="C virus receiving pegylated interferon and ribavirin. Hepatology2010;51:1122‐1126.20069649 20collab:"/>
 <result pre="Panel ; ChungRT, DavisGL, JensenDM, MasurH, SaagMS, ThomasDL, et al." exact="Hepatitis" post="C guidance: AASLD‐IDSA recommendations for testing, managing, and treating"/>
 <result pre="AASLD‐IDSA recommendations for testing, managing, and treating adults infected with" exact="hepatitis" post="C virus. Hepatology2015;62:932‐954.26111063 21collab: AASLD‐IDSA . Recommendations for testing,"/>
 <result pre="Hepatology2015;62:932‐954.26111063 21collab: AASLD‐IDSA . Recommendations for testing, managing, and treating" exact="hepatitis" post="C. http://www.hcvguidelines.org. Accessed November 25, 2019. 22MückeMM, MückeVT, LangeCM,"/>
 <result pre="November 25, 2019. 22MückeMM, MückeVT, LangeCM, ZeuzemS. Special populations: treating" exact="hepatitis" post="C in patients with decompensated cirrhosis and/or advanced renal"/>
 <result pre="ZeuzemS. Special populations: treating hepatitis C in patients with decompensated" exact="cirrhosis" post="and/or advanced renal impairment. Liver Int2017;37:19‐25. 23PolS, ParlatiL. Treatment"/>
 <result pre="and/or advanced renal impairment. Liver Int2017;37:19‐25. 23PolS, ParlatiL. Treatment of" exact="hepatitis" post="C: the use of the new pangenotypic direct‐acting antivirals"/>
 <result pre="FontanaRJ, YangR, et al. Daclatasvir with sofosbuvir and ribavirin for" exact="hepatitis" post="C virus infection with advanced cirrhosis or post‐liver transplantation"/>
 <result pre="et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C" exact="virus infection" post="with advanced cirrhosis or post‐liver transplantation recurrence. Hepatology2016;63:1493‐1505.26754432 25Falade‐NwuliaO,"/>
 <result pre="al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus" exact="infection" post="with advanced cirrhosis or post‐liver transplantation recurrence. Hepatology2016;63:1493‐1505.26754432 25Falade‐NwuliaO,"/>
 <result pre="sofosbuvir and ribavirin for hepatitis C virus infection with advanced" exact="cirrhosis" post="or post‐liver transplantation recurrence. Hepatology2016;63:1493‐1505.26754432 25Falade‐NwuliaO, Suarez‐CuervoC, NelsonDR, FriedMW,"/>
 <result pre="Suarez‐CuervoC, NelsonDR, FriedMW, SegalJB, SulkowskiMS. Oral direct‐acting agent therapy for" exact="hepatitis" post="C virus infection: a systematic review. Ann Intern Med2017;166:637‐648.28319996"/>
 <result pre="review. Ann Intern Med2017;166:637‐648.28319996 26collab: World Health Organization . Combating" exact="Hepatitis" post="B and C to Reach Elimination by 2030: Advocacy"/>
 <result pre="Organization; 2016. 27RazaviH, Sanchez GonzalezY, PangeriA, CornbergM. Global timing of" exact="hepatitis" post="C virus elimination: estimating the year countries will achieve"/>
 <result pre="Health Organization elimination targets. J Hepatol2019;70:e748. 28HolmbergSD, SpradlingPR, MoormanAC, DennistonMM." exact="Hepatitis" post="C in the United States. N Engl J Med2013;368:1859‐1861.23675657"/>
 <result pre="Med2013;368:1859‐1861.23675657 29LinasBP, BarterDM, LeffJA, AssoumouSA, SalomonJA, WeinsteinMC, et al. The" exact="hepatitis" post="C cascade of care: identifying priorities to improve clinical"/>
 <result pre="30YehiaBR, SchranzAJ, UmscheidCA, Lo ReV, 3rd. The treatment cascade for" exact="chronic hepatitis" post="C virus infection in the United States: a systematic"/>
 <result pre="SchranzAJ, UmscheidCA, Lo ReV, 3rd. The treatment cascade for chronic" exact="hepatitis" post="C virus infection in the United States: a systematic"/>
 <result pre="Lo ReV, 3rd. The treatment cascade for chronic hepatitis C" exact="virus infection" post="in the United States: a systematic review and meta‐analysis."/>
 <result pre="ReV, 3rd. The treatment cascade for chronic hepatitis C virus" exact="infection" post="in the United States: a systematic review and meta‐analysis."/>
 <result pre="PatientRN. Flow Across Physician Specialties Over the Course of the" exact="Hepatitis" post="C Care Cascade: A Real‐World Analysis from the United"/>
 <result pre="CraigieA, GibsonA, DesmondP, WongD, et al. Outcomes of treatment for" exact="hepatitis" post="C in prisoners using a nurse‐led, statewide model of"/>
 <result pre="Clinical effectiveness of pharmacy‐led versus conventionally delivered antiviral treatment for" exact="hepatitis" post="C in patients receiving opioid substitution therapy: a study"/>
 <result pre="DumontIP, HeinzowHS, HuttonDW. Cost‐effectiveness of access expansion to treatment of" exact="hepatitis" post="C virus infection through primary care providers. Gastroenterology2017;153:1531‐1543.e1532.29074450 35CroughanP,"/>
 <result pre="HuttonDW. Cost‐effectiveness of access expansion to treatment of hepatitis C" exact="virus infection" post="through primary care providers. Gastroenterology2017;153:1531‐1543.e1532.29074450 35CroughanP, GeeRE. How should"/>
 <result pre="Cost‐effectiveness of access expansion to treatment of hepatitis C virus" exact="infection" post="through primary care providers. Gastroenterology2017;153:1531‐1543.e1532.29074450 35CroughanP, GeeRE. How should"/>
 <result pre="access expansion to treatment of hepatitis C virus infection through" exact="primary" post="care providers. Gastroenterology2017;153:1531‐1543.e1532.29074450 35CroughanP, GeeRE. How should physicians steward"/>
 <result pre="primary care providers. Gastroenterology2017;153:1531‐1543.e1532.29074450 35CroughanP, GeeRE. How should physicians steward" exact="limited" post="resources while ensuring that patients can access needed medicines?AMA"/>
 <result pre="Ethics2019;21:630‐635. 36CoyleC, MoormanAC, BartholomewT, KleinG, KwakwaH, MehtaSH, et al. The" exact="hepatitis" post="C virus care continuum: linkage to hepatitis C virus"/>
 <result pre="et al. The hepatitis C virus care continuum: linkage to" exact="hepatitis" post="C virus care and treatment among patients at an"/>
 <result pre="network. Hepatology2019;70:476‐486.30633811 37WoolleyAE, SinghSK, GoldbergHJ, MallidiHR, GivertzMM, MehraMR, et al." exact="Heart" post="and lung transplants from HCV‐infected donors to uninfected recipients."/>
 <result pre="WongWWL, SanderB, BellCM, MumtazK, KowgierM, et al. Cost effectiveness of" exact="hepatocellular carcinoma" post="surveillance after a sustained virologic response to therapy in"/>
 <result pre="SanderB, BellCM, MumtazK, KowgierM, et al. Cost effectiveness of hepatocellular" exact="carcinoma" post="surveillance after a sustained virologic response to therapy in"/>
 <result pre="after a sustained virologic response to therapy in patients with" exact="hepatitis" post="C virus infection and advanced fibrosis. Clin Gastroenterol Hepatol2019;17:1840‐1849.e1816.30580095"/>
 <result pre="sustained virologic response to therapy in patients with hepatitis C" exact="virus infection" post="and advanced fibrosis. Clin Gastroenterol Hepatol2019;17:1840‐1849.e1816.30580095 39WongRJ, AguilarM, CheungR,"/>
 <result pre="virologic response to therapy in patients with hepatitis C virus" exact="infection" post="and advanced fibrosis. Clin Gastroenterol Hepatol2019;17:1840‐1849.e1816.30580095 39WongRJ, AguilarM, CheungR,"/>
 <result pre="Gastroenterol Hepatol2019;17:1840‐1849.e1816.30580095 39WongRJ, AguilarM, CheungR, PerumpailRB, HarrisonSA, YounossiZM, et al." exact="Nonalcoholic" post="steatohepatitis is the second leading etiology of liver disease"/>
 <result pre="YounossiZM, et al. Nonalcoholic steatohepatitis is the second leading etiology" exact="of liver" post="disease among adults awaiting liver transplantation in the United"/>
 <result pre="et al. Nonalcoholic steatohepatitis is the second leading etiology of" exact="liver disease" post="among adults awaiting liver transplantation in the United States."/>
 <result pre="al. Nonalcoholic steatohepatitis is the second leading etiology of liver" exact="disease" post="among adults awaiting liver transplantation in the United States."/>
 <result pre="AnsteeQM, MariettiM, HardyT, HenryL, EslamM, et al. Global burden of" exact="NAFLD" post="and NASH: trends, predictions, risk factors and prevention. Nat"/>
 <result pre="Changes in the prevalence of the most common causes of" exact="chronic" post="liver diseases in the United States from 1988 to"/>
 <result pre="liver function and body composition by direct‐acting antiviral therapy for" exact="hepatitis" post="C virus infection. Hepatol Res2018;48:337‐344.29115717 43SchlevogtB, DeterdingK, PortK, SiederdissenCHZ,"/>
 <result pre="and body composition by direct‐acting antiviral therapy for hepatitis C" exact="virus infection." post="Hepatol Res2018;48:337‐344.29115717 43SchlevogtB, DeterdingK, PortK, SiederdissenCHZ, SollikL, KirschnerJ, et"/>
 <result pre="DeterdingK, PortK, SiederdissenCHZ, SollikL, KirschnerJ, et al. Interferon‐free cure of" exact="chronic" post="Hepatitis C is associated with weight gain during long‐term"/>
 <result pre="PortK, SiederdissenCHZ, SollikL, KirschnerJ, et al. Interferon‐free cure of chronic" exact="Hepatitis" post="C is associated with weight gain during long‐term follow‐up."/>
 <result pre="45SchweitzerA, HornJ, MikolajczykRT, KrauseG, OttJJ. Estimations of worldwide prevalence of" exact="chronic hepatitis" post="B virus infection: a systematic review of data published"/>
 <result pre="HornJ, MikolajczykRT, KrauseG, OttJJ. Estimations of worldwide prevalence of chronic" exact="hepatitis" post="B virus infection: a systematic review of data published"/>
 <result pre="YouS‐L, ChenC‐J, LiuC‐J, LaiM‐W, WuT‐C, et al. Long‐term effects of" exact="hepatitis" post="B immunization of infants in preventing liver cancer. Gastroenterology2016;151:472‐480.e471.27269245"/>
 <result pre="Long‐term effects of hepatitis B immunization of infants in preventing" exact="liver cancer." post="Gastroenterology2016;151:472‐480.e471.27269245 47NiY‐H, ChangM‐H, JanC‐F, HsuH‐Y, ChenH‐L, WuJ‐F, et al."/>
 <result pre="ChangM‐H, JanC‐F, HsuH‐Y, ChenH‐L, WuJ‐F, et al. Continuing decrease in" exact="hepatitis" post="B virus infection 30 years after initiation of infant"/>
 <result pre="HsuH‐Y, ChenH‐L, WuJ‐F, et al. Continuing decrease in hepatitis B" exact="virus infection" post="30 years after initiation of infant vaccination program in"/>
 <result pre="ChenH‐L, WuJ‐F, et al. Continuing decrease in hepatitis B virus" exact="infection" post="30 years after initiation of infant vaccination program in"/>
 <result pre="ReisingerK, KabongoML, et al. Immunogenicity and safety of an investigational" exact="hepatitis" post="B vaccine with a toll‐like receptor 9 agonist adjuvant"/>
 <result pre="toll‐like receptor 9 agonist adjuvant (HBsAg‐1018) compared to a licensed" exact="hepatitis" post="B vaccine in healthy adults 40‐70 years of age."/>
 <result pre="the Advisory Committee on Immunization Practices for use of a" exact="hepatitis" post="B vaccine with a novel adjuvant. Morb Mortal Wkly"/>
 <result pre="et al. Long term treatment with tenofovir disoproxil fumarate for" exact="chronic hepatitis" post="B infection is safe and well tolerated and associated"/>
 <result pre="al. Long term treatment with tenofovir disoproxil fumarate for chronic" exact="hepatitis" post="B infection is safe and well tolerated and associated"/>
 <result pre="term treatment with tenofovir disoproxil fumarate for chronic hepatitis B" exact="infection" post="is safe and well tolerated and associated with durable"/>
 <result pre=". EASL 2017 Clinical Practice Guidelines on the management of" exact="hepatitis" post="B virus infection. J Hepatol2017;67:370‐398.28427875 52TerraultNA, LokASF, McMahonBJ, ChangKM,"/>
 <result pre="2017 Clinical Practice Guidelines on the management of hepatitis B" exact="virus infection." post="J Hepatol2017;67:370‐398.28427875 52TerraultNA, LokASF, McMahonBJ, ChangKM, HwangJP, JonasMM, et"/>
 <result pre="JonasMM, et al. Update on prevention, diagnosis, and treatment of" exact="chronic hepatitis" post="B: AASLD 2018 hepatitis B guidance. Hepatology2018;67:1560‐1599.29405329 53LamperticoP, ChanH,"/>
 <result pre="et al. Update on prevention, diagnosis, and treatment of chronic" exact="hepatitis" post="B: AASLD 2018 hepatitis B guidance. Hepatology2018;67:1560‐1599.29405329 53LamperticoP, ChanH,"/>
 <result pre="prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018" exact="hepatitis" post="B guidance. Hepatology2018;67:1560‐1599.29405329 53LamperticoP, ChanH, JanssenH, StrasserS, SchindlerR, BergT."/>
 <result pre="weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for" exact="hepatitis" post="B virus infection. J Hepatol2018;68:672‐681.29756595 55LiangTJ, BlockTM, McMahonBJ, GhanyMG,"/>
 <result pre="of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B" exact="virus infection." post="J Hepatol2018;68:672‐681.29756595 55LiangTJ, BlockTM, McMahonBJ, GhanyMG, UrbanS, GuoJT, et"/>
 <result pre="GhanyMG, UrbanS, GuoJT, et al. Present and future therapies of" exact="hepatitis" post="B: from discovery to cure. Hepatology2015;62:1893‐1908.26239691 56CornbergM, LokAS‐F, TerraultNA,"/>
 <result pre="al. Guidance for design and endpoints of clinical trials in" exact="chronic hepatitis" post="B‐report from the 2019 EASL‐AASLD HBV Treatment Endpoints Conference."/>
 <result pre="Guidance for design and endpoints of clinical trials in chronic" exact="hepatitis" post="B‐report from the 2019 EASL‐AASLD HBV Treatment Endpoints Conference."/>
 <result pre="print] 57WeigandJ, WedemeyerH, FingerA, HeidrichB, RosenauJ, MichelG. A decline in" exact="hepatitis" post="B virus surface antigen (hbsag) predicts clearance, but does"/>
 <result pre="of quantitative assay of HBsAg and HBV DNA levels during" exact="chronic" post="HBV treatment. Dig Dis Sci2008;53:2995‐2998.18409002 59GierschK, AllweissL, VolzT, DandriM,"/>
 <result pre="J Hepatol2017;66:460‐462.27826059 60MakLY, WongDK, CheungKS, SetoWK, LaiCL, YuenMF. Review article:" exact="hepatitis" post="B core‐related antigen (HBcrAg): an emerging marker for chronic"/>
 <result pre="article: hepatitis B core‐related antigen (HBcrAg): an emerging marker for" exact="chronic hepatitis" post="B virus infection. Aliment Pharmacol Ther2018;47:43‐54.29035003 61TestoniB, LebosséF, ScholtesC,"/>
 <result pre="hepatitis B core‐related antigen (HBcrAg): an emerging marker for chronic" exact="hepatitis" post="B virus infection. Aliment Pharmacol Ther2018;47:43‐54.29035003 61TestoniB, LebosséF, ScholtesC,"/>
 <result pre="core‐related antigen (HBcrAg): an emerging marker for chronic hepatitis B" exact="virus infection." post="Aliment Pharmacol Ther2018;47:43‐54.29035003 61TestoniB, LebosséF, ScholtesC, BerbyF, MiagliaC, SubicM,"/>
 <result pre="Ther2018;47:43‐54.29035003 61TestoniB, LebosséF, ScholtesC, BerbyF, MiagliaC, SubicM, et al. Serum" exact="hepatitis" post="B core‐related antigen (HBcrAg) correlates with covalently closed circular"/>
 <result pre="(HBcrAg) correlates with covalently closed circular DNA transcriptional activity in" exact="chronic hepatitis" post="B patients. J Hepatol2019;70:615‐625.30529504 62HosakaT, SuzukiF, KobayashiM, HirakawaM, KawamuraY,"/>
 <result pre="correlates with covalently closed circular DNA transcriptional activity in chronic" exact="hepatitis" post="B patients. J Hepatol2019;70:615‐625.30529504 62HosakaT, SuzukiF, KobayashiM, HirakawaM, KawamuraY,"/>
 <result pre="et al. HBcrAg is a predictor of post‐treatment recurrence of" exact="hepatocellular carcinoma" post="during antiviral therapy. Liver Int2010;30:1461‐1470.20840396 63XiaY, LiangTJ. Development of"/>
 <result pre="al. HBcrAg is a predictor of post‐treatment recurrence of hepatocellular" exact="carcinoma" post="during antiviral therapy. Liver Int2010;30:1461‐1470.20840396 63XiaY, LiangTJ. Development of"/>
 <result pre="Development of direct‐acting antiviral and host‐targeting agents for treatment of" exact="hepatitis" post="B virus infection. Gastroenterology2019;156:311‐324.30243618 64TangLS, CovertE, WilsonE, KottililS. Chronic"/>
 <result pre="direct‐acting antiviral and host‐targeting agents for treatment of hepatitis B" exact="virus infection." post="Gastroenterology2019;156:311‐324.30243618 64TangLS, CovertE, WilsonE, KottililS. Chronic hepatitis B infection:"/>
 <result pre="of hepatitis B virus infection. Gastroenterology2019;156:311‐324.30243618 64TangLS, CovertE, WilsonE, KottililS." exact="Chronic" post="hepatitis B infection: a review. JAMA2018;319:1802‐1813.29715359 65FattovichG, GiustinaG, ChristensenE,"/>
 <result pre="hepatitis B virus infection. Gastroenterology2019;156:311‐324.30243618 64TangLS, CovertE, WilsonE, KottililS. Chronic" exact="hepatitis" post="B infection: a review. JAMA2018;319:1802‐1813.29715359 65FattovichG, GiustinaG, ChristensenE, PantalenaM,"/>
 <result pre="65FattovichG, GiustinaG, ChristensenE, PantalenaM, ZagniI, RealdiG, et al. Influence of" exact="hepatitis" post="delta virus infection on morbidity and mortality in compensated"/>
 <result pre="ChristensenE, PantalenaM, ZagniI, RealdiG, et al. Influence of hepatitis delta" exact="virus infection" post="on morbidity and mortality in compensated cirrhosis type B."/>
 <result pre="PantalenaM, ZagniI, RealdiG, et al. Influence of hepatitis delta virus" exact="infection" post="on morbidity and mortality in compensated cirrhosis type B."/>
 <result pre="hepatitis delta virus infection on morbidity and mortality in compensated" exact="cirrhosis" post="type B. Gut2000;46:420‐426.10673308 66FattovichG, BortolottiF, DonatoF. Natural history of"/>
 <result pre="delta virus infection on morbidity and mortality in compensated cirrhosis" exact="type B." post="Gut2000;46:420‐426.10673308 66FattovichG, BortolottiF, DonatoF. Natural history of chronic hepatitis"/>
 <result pre="cirrhosis type B. Gut2000;46:420‐426.10673308 66FattovichG, BortolottiF, DonatoF. Natural history of" exact="chronic hepatitis" post="B: special emphasis on disease progression and prognostic factors."/>
 <result pre="type B. Gut2000;46:420‐426.10673308 66FattovichG, BortolottiF, DonatoF. Natural history of chronic" exact="hepatitis" post="B: special emphasis on disease progression and prognostic factors."/>
 <result pre="DonatoF. Natural history of chronic hepatitis B: special emphasis on" exact="disease" post="progression and prognostic factors. J Hepatol2008;48:335‐352.18096267 67ChenH‐Y, ShenD‐T, JiD‐Z,"/>
 <result pre="JiD‐Z, HanP‐C, ZhangW‐M, MaJ‐F, et al. Prevalence and burden of" exact="hepatitis" post="D virus infection in the global population: a systematic"/>
 <result pre="ZhangW‐M, MaJ‐F, et al. Prevalence and burden of hepatitis D" exact="virus infection" post="in the global population: a systematic review and meta‐analysis."/>
 <result pre="MaJ‐F, et al. Prevalence and burden of hepatitis D virus" exact="infection" post="in the global population: a systematic review and meta‐analysis."/>
 <result pre="and meta‐analysis. Gut2019;68:512‐521. 68PatelEU, ThioCL, BoonD, ThomasDL, TobianAA. Prevalence of" exact="hepatitis" post="B and hepatitis D virus infections in the United"/>
 <result pre="68PatelEU, ThioCL, BoonD, ThomasDL, TobianAA. Prevalence of hepatitis B and" exact="hepatitis" post="D virus infections in the United States, 2011‐2016. Clin"/>
 <result pre="ThomasDL, TobianAA. Prevalence of hepatitis B and hepatitis D virus" exact="infections" post="in the United States, 2011‐2016. Clin Infect Dis2019;69:709‐712.30605508 69LemppFA,"/>
 <result pre="the United States, 2011‐2016. Clin Infect Dis2019;69:709‐712.30605508 69LemppFA, NiY, UrbanS." exact="Hepatitis" post="delta virus: insights into a peculiar pathogen and novel"/>
 <result pre="Rev Gastroenterol Hepatol2016;13:580‐589.27534692 70MenthaN, ClementS, NegroF, AlfaiateD. A review on" exact="hepatitis" post="D: from virology to new therapies. J Adv Res2019;17:3‐15.31193285"/>
 <result pre="et al. Peginterferon plus adefovir versus either drug alone for" exact="hepatitis" post="delta. N Engl J Med2011;364:322‐331.21268724 72KohC, CaniniL, DahariH, ZhaoX,"/>
 <result pre="UprichardSL, Haynes‐WilliamsV, et al. Oral prenylation inhibition with lonafarnib in" exact="chronic hepatitis" post="D infection: a proof‐of‐concept randomised, double‐blind, placebo‐controlled phase 2A"/>
 <result pre="Haynes‐WilliamsV, et al. Oral prenylation inhibition with lonafarnib in chronic" exact="hepatitis" post="D infection: a proof‐of‐concept randomised, double‐blind, placebo‐controlled phase 2A"/>
 <result pre="KaratayliE, et al. Optimizing lonafarnib treatment for the management of" exact="chronic" post="delta hepatitis: the LOWR HDV‐1 study. Hepatology2018;67:1224‐1236.29152762 74NiY, LemppFA,"/>
 <result pre="study. Hepatology2018;67:1224‐1236.29152762 74NiY, LemppFA, MehrleS, NkongoloS, KaufmanC, FälthM, et al." exact="Hepatitis" post="B and D viruses exploit sodium taurocholate co‐transporting polypeptide"/>
 <result pre="Accessed December 15, 2019. 76CornbergM, MannsMP. Hepatitis: no cure for" exact="hepatitis" post="B and D without targeting integrated viral DNA?Nat Rev"/>
 <result pre="no cure for hepatitis B and D without targeting integrated" exact="viral" post="DNA?Nat Rev Gastroenterol Hepatol2018;15:195‐196.29382951 77WooddellCI, YuenM‐F, ChanHL‐Y, GishRG, LocarniniSA,"/>
 <result pre="treatment of chronically infected patients and chimpanzees reveals that integrated" exact="hepatitis" post="B virus DNA is a source of HBsAg. Sci"/>
 <result pre="Sci Transl Med2017;9:eaan0241.28954926 78collab: World Health Organization . Guidelines on" exact="Hepatitis" post="B and C Testing: Policy Brief. Geneva, Switzerland: World"/>
 <result pre="Guidelines for the Care and Treatment of Persons Diagnosed With" exact="Chronic" post="Hepatitis C Virus Infection. Geneva, Switzerland: World Health Organization;"/>
 <result pre="for the Care and Treatment of Persons Diagnosed With Chronic" exact="Hepatitis" post="C Virus Infection. Geneva, Switzerland: World Health Organization; 2018."/>
 <result pre="Study of the Liver . EASL recommendations on treatment of" exact="hepatitis" post="C 2018. J Hepatol2018;69:461‐511.29650333 81MoyerVA. Screening for hepatitis C"/>
 <result pre="treatment of hepatitis C 2018. J Hepatol2018;69:461‐511.29650333 81MoyerVA. Screening for" exact="hepatitis" post="C virus infection in adults: US Preventive Services Task"/>
 <result pre="hepatitis C 2018. J Hepatol2018;69:461‐511.29650333 81MoyerVA. Screening for hepatitis C" exact="virus infection" post="in adults: US Preventive Services Task Force recommendation statement."/>
 <result pre="C 2018. J Hepatol2018;69:461‐511.29650333 81MoyerVA. Screening for hepatitis C virus" exact="infection" post="in adults: US Preventive Services Task Force recommendation statement."/>
 <result pre="BzowejNH, ChangKM, HwangJP, JonasMM, MuradMH. AASLD guidelines for treatment of" exact="chronic hepatitis" post="B. Hepatology2016;63:261‐283.26566064 Author names in bold designate shared co‐first"/>
 <result pre="ChangKM, HwangJP, JonasMM, MuradMH. AASLD guidelines for treatment of chronic" exact="hepatitis" post="B. Hepatology2016;63:261‐283.26566064 Author names in bold designate shared co‐first"/>
</results>
